Galera Therapeutics
Malvern, US · Founded 2012 · 7 employees on LinkedIn · 2 known investors
Find your way into Galera Therapeutics
146 people in our graph share verified history with the Galera Therapeutics team — schools, employers, funds. One of them is your warm intro.
Catherine Matthesunlockedknows Robert A. Beardsley · together at Kereos (overlapped)
×11knows the team · via University of Iowa
Galera Therapeutics is a biotechnology company developing antibody-based and other therapeutics. This page profiles Dr. Nancy Chang, a member of the company's Board of Directors.
Founders & leadership
Galera Therapeutics was founded in 2012 by Mel Sorensen.
MS
Mel SorenseninFounder · Chairman, President & CEO2012–2026
JS
Joel SussmaninExecutive
JL
Jeffery L. KeeneinVP Research2009–2021
DP
Dennis P. RileyinCSO
JT
Jon T. HolmlundExecutive
RA
Robert A. BeardsleyinCo-Founder, Executive Chair & Chief Operating Officer2009–2024Robert A. Beardsley holds a PhD and has led multiple biotechnology companies from startup through public markets, with experience spanning drug discovery, clinical development, and commercialization across oncology and other therapeutic areas. He serves as Chief Executive Officer and Director at Galera Therapeutics, which he co-led from inception through NDA filing of its lead candidate while raising over $150 million in venture funding and completing an IPO.
JM
J. Mel SorensenNamed on SEC filing
Board
HS
Henry SkinnerBoard director
FT
Frank TortiBoard director
CM
JB
James BarrettBoard director
MR
Michael R. FriedmanBoard director
Investors · 2
Reported raises · per SEC filings
Form D private placements$132.7M disclosed across 6 rounds · 2014–2024
▶$2.9MraisedJan 2025 · 8 investors · PharmaceuticalsRule 506(b)
▶$2.9MraisedJan 2025 · 8 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Nancy T. ChangDirector
- J. Mel SorensenExecutive Officer, Director
- Kevin LokayDirector
- Michael R. FriedmanDirector
- Lawrence AllevaDirector
- Joel SussmanExecutive Officer
- Offering amount
- $2.9M
- Amount sold
- $2.9M
- First sale
- Dec 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$2.7MraisedJan 2025 · 18 investors · PharmaceuticalsRule 506(b)
▶$2.7MraisedJan 2025 · 18 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Michael R. FriedmanDirector
- Joel SussmanExecutive Officer
- Nancy T. ChangDirector
- Kevin LokayDirector
- J. Mel SorensenExecutive Officer, Director
- Lawrence AllevaDirector
- Offering amount
- $2.7M
- Amount sold
- $2.7M
- First sale
- Dec 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$70.2MraisedSep 2018 · 23 investors · PharmaceuticalsRule 506(b)
▶$70.2MraisedSep 2018 · 23 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Michal SilverbergDirector
- Thomas DyrbergDirector
- Stephen RossExecutive Officer
- Arthur FratamicoExecutive Officer
- Joel SussmanExecutive Officer
- Dennis P. RileyExecutive Officer
- Jon T. HolmlundExecutive Officer
- Robert A. BeardsleyExecutive Officer, Director
- J. Mel SorensenExecutive Officer, Director
- Michael PowellDirector
- Campbell MurrayDirector
- Offering amount
- $70.2M
- Amount sold
- $70.2M
- First sale
- Aug 2018
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$15MraisedNov 2016 · 1 investors · PharmaceuticalsRule 506(b)
▶$15MraisedNov 2016 · 1 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- James BarrettDirector
- Joel SussmanExecutive Officer
- Frank TortiDirector
- Jon T. HolmlundExecutive Officer
- Campbell MurrayDirector
- Henry SkinnerDirector
- Dennis P. RileyExecutive Officer
- J. Mel SorensenExecutive Officer, Director
- Robert A. BeardsleyExecutive Officer, Director
- Thomas DyrbergDirector
- Offering amount
- $15M
- Amount sold
- $15M
- First sale
- Nov 2016
- Incorporated
- Corporation, Delaware, 2012
- Federal exemptions
- 06b
▶$37.1MraisedOct 2015 · 7 investors · PharmaceuticalsRule 506(b)
▶$37.1MraisedOct 2015 · 7 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Jeffery L. KeeneExecutive Officer
- Henry SkinnerDirector
- Joel SussmanExecutive Officer
- Frank TortiDirector
- Campbell MurrayDirector
- Mel SorensenExecutive Officer, Director
- Dennis P. RileyExecutive Officer
- Jon T. HolmlundExecutive Officer
- Robert A. BeardsleyExecutive Officer, Director
- James BarrettDirector
- Offering amount
- $37.1M
- Amount sold
- $37.1M
- First sale
- Oct 2015
- Incorporated
- Corporation, Delaware, 2012
- Federal exemptions
- 06b
▶$4.7MraisedAug 2014 · 7 investors · BiotechnologyRule 506(b)
▶$4.7MraisedAug 2014 · 7 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Henry SkinnerDirector
- James BarrettDirector
- Frank TortiDirector
- Mel SorensenExecutive Officer, Director
- Campbell MurrayDirector
- Robert A. BeardsleyExecutive Officer, Director
- Joel SussmanExecutive Officer
- Offering amount
- $9.5M
- Amount sold
- $4.7M
- Minimum investment
- $25K
- Proceeds to insiders
- $850K
- First sale
- Jul 2014
- Incorporated
- Corporation, Delaware, 2012
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 3
by search overlap
Robinhood13 shared keywordsRobinhood is a financial trading platform that enables users to manage portfolios across stocks, ETFs, cryptocurrencies, options, futures, and prediction markets. The platform serves retail investors with low barriers to entry, offering portfolio management services and market insights.
StockTwits12 shared keywordsStocktwits operates an online community platform where investors and traders share ideas, analysis, and trade discussions organized around stock tickers. The page presented is its community guidelines rather than a product description.
AbCellera11 shared keywordsAbCellera develops antibody-based medicines using a technology platform that integrates biology, computation, and engineering, working with pharmaceutical partners on antibody drug programs including bispecifics and antibody drug conjugates. The company operates in the biotech and drug discovery sector, focusing on first-in-class and best-in-class antibody therapeutics for complex targets such as transmembrane proteins.
Companies competing with Galera Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.
Non-dilutive funding · 2 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2020 | $868.7K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2017 | $224.7K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
Frequently asked questions
- What does Galera Therapeutics do?
- Galera Therapeutics is a biotechnology company developing antibody-based and other therapeutics. This page profiles Dr. Nancy Chang, a member of the company's Board of Directors.
- Who founded Galera Therapeutics?
- Galera Therapeutics was founded by Mel Sorensen in 2012.
- Who are Galera Therapeutics's investors?
- Galera Therapeutics's investors include New Enterprise Associates (NEA), Sofinnova Ventures.
- How much funding has Galera Therapeutics raised?
- Galera Therapeutics has disclosed $132.7M raised across 6 rounds.
- Where is Galera Therapeutics headquartered?
- Galera Therapeutics is headquartered in Malvern, US.